Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
17 7月 2018
Brexit White Paper highlights importance of Intellectual Property rights post-Brexit
9 7月 2018
Patent and Pharma Update, July 2018
9 7月 2018
Comments on UK proposal for the future relationship with the EU
29 5月 2018
Pfizer beats the ACCC again – implications for pharma
25 4月 2018
ADVOCATE GENERAL PROVIDES OPINION ON THE INTERPRETATION OF ARTICLE 3(a) SPC REGULATION
23 4月 2018
Enforcement of IP judgments in foreign countries: Government seeks input for international convention
16 4月 2018
2018 Guide to Enterprise Bargaining under the Fair Work Act
26 3月 2018
New Horizons: The 2017 Australian IPO Review
22 3月 2018
Use it or lose it: are trade marks owned by the right entity?
9 3月 2018
Data use: Protecting a critical resource
23 2月 2018
Text of the revised Trans-Pacific Partnership agreement released
21 2月 2018
Arbitrating Pharma Disputes On The Rise – Planning Ahead Makes Sense
